273 related articles for article (PubMed ID: 23969884)
1. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884
[TBL] [Abstract][Full Text] [Related]
2. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Huang TT; Parab S; Burnett R; Diago O; Ostertag D; Hofman FM; Espinoza FL; Martin B; Ibañez CE; Kasahara N; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Hum Gene Ther; 2015 Feb; 26(2):82-93. PubMed ID: 25419577
[TBL] [Abstract][Full Text] [Related]
3. Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Yagiz K; Huang TT; Lopez Espinoza F; Mendoza D; Ibañez CE; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2016 Oct; 18(10):1390-401. PubMed ID: 27166379
[TBL] [Abstract][Full Text] [Related]
4. Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Philbrick BD; Adamson DC
Expert Opin Investig Drugs; 2019 Mar; 28(3):207-216. PubMed ID: 30676111
[TBL] [Abstract][Full Text] [Related]
5. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Cloughesy TF; Landolfi J; Vogelbaum MA; Ostertag D; Elder JB; Bloomfield S; Carter B; Chen CC; Kalkanis SN; Kesari S; Lai A; Lee IY; Liau LM; Mikkelsen T; Nghiemphu P; Piccioni D; Accomando W; Diago OR; Hogan DJ; Gammon D; Kasahara N; Kheoh T; Jolly DJ; Gruber HE; Das A; Walbert T
Neuro Oncol; 2018 Sep; 20(10):1383-1392. PubMed ID: 29762717
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Miller CR; Williams CR; Buchsbaum DJ; Gillespie GY
Cancer Res; 2002 Feb; 62(3):773-80. PubMed ID: 11830532
[TBL] [Abstract][Full Text] [Related]
7. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Cloughesy TF; Petrecca K; Walbert T; Butowski N; Salacz M; Perry J; Damek D; Bota D; Bettegowda C; Zhu JJ; Iwamoto F; Placantonakis D; Kim L; Elder B; Kaptain G; Cachia D; Moshel Y; Brem S; Piccioni D; Landolfi J; Chen CC; Gruber H; Rao AR; Hogan D; Accomando W; Ostertag D; Montellano TT; Kheoh T; Kabbinavar F; Vogelbaum MA
JAMA Oncol; 2020 Dec; 6(12):1939-1946. PubMed ID: 33119048
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
Takahashi M; Valdes G; Hiraoka K; Inagaki A; Kamijima S; Micewicz E; Gruber HE; Robbins JM; Jolly DJ; McBride WH; Iwamoto KS; Kasahara N
Cancer Gene Ther; 2014 Oct; 21(10):405-410. PubMed ID: 25301172
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Cloughesy TF; Landolfi J; Hogan DJ; Bloomfield S; Carter B; Chen CC; Elder JB; Kalkanis SN; Kesari S; Lai A; Lee IY; Liau LM; Mikkelsen T; Nghiemphu PL; Piccioni D; Walbert T; Chu A; Das A; Diago OR; Gammon D; Gruber HE; Hanna M; Jolly DJ; Kasahara N; McCarthy D; Mitchell L; Ostertag D; Robbins JM; Rodriguez-Aguirre M; Vogelbaum MA
Sci Transl Med; 2016 Jun; 8(341):341ra75. PubMed ID: 27252174
[TBL] [Abstract][Full Text] [Related]
10. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Mitchell LA; Lopez Espinoza F; Mendoza D; Kato Y; Inagaki A; Hiraoka K; Kasahara N; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2017 Jul; 19(7):930-939. PubMed ID: 28387849
[TBL] [Abstract][Full Text] [Related]
11. Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.
Accomando WP; Rao AR; Hogan DJ; Newman AM; Nakao A; Alizadeh AA; Diehn M; Diago OR; Gammon D; Haghighi A; Gruber HE; Jolly DJ; Ostertag D
Clin Cancer Res; 2020 Dec; 26(23):6176-6186. PubMed ID: 32816892
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR
Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943
[TBL] [Abstract][Full Text] [Related]
13. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
14. In vivo preclinical low-field MRI monitoring of tumor growth following a suicide-gene therapy in an orthotopic mice model of human glioblastoma.
Breton E; Goetz C; Kintz J; Accart N; Aubertin G; Grellier B; Erbs P; Rooke R; Constantinesco A; Choquet P
C R Biol; 2010 Mar; 333(3):220-5. PubMed ID: 20338540
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Lin CJ; Lee CC; Shih YL; Lin TY; Wang SH; Lin YF; Shih CM
Free Radic Biol Med; 2012 Jan; 52(2):377-91. PubMed ID: 22094224
[TBL] [Abstract][Full Text] [Related]
16. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
[TBL] [Abstract][Full Text] [Related]
17. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
[TBL] [Abstract][Full Text] [Related]
18. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
19. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Ostertag D; Amundson KK; Lopez Espinoza F; Martin B; Buckley T; Galvão da Silva AP; Lin AH; Valenta DT; Perez OD; Ibañez CE; Chen CI; Pettersson PL; Burnett R; Daublebsky V; Hlavaty J; Gunzburg W; Kasahara N; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2012 Feb; 14(2):145-59. PubMed ID: 22070930
[TBL] [Abstract][Full Text] [Related]
20. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
